[{"id":"239cfbfd-4502-4f5e-a5da-4b96cfe72590","acronym":"","url":"https://clinicaltrials.gov/study/NCT07498400","created_at":"2026-04-04T01:40:42.252Z","updated_at":"2026-04-04T01:40:42.252Z","phase":"","brief_title":"Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer","source_id_and_acronym":"NCT07498400","lead_sponsor":"Xijing Hospital","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2026-03-27"},{"id":"855e0615-efe8-444c-a20c-79fd80778922","acronym":"","url":"https://clinicaltrials.gov/study/NCT07475923","created_at":"2026-03-28T01:38:45.775Z","updated_at":"2026-03-28T01:38:45.775Z","phase":"","brief_title":"Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)","source_id_and_acronym":"NCT07475923","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • BRCA","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation","tags":["HER-2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 08/26/2026","start_date":" 08/26/2026","primary_txt":" Primary completion: 12/31/2031","primary_completion_date":" 12/31/2031","study_txt":" Completion: 12/31/2033","study_completion_date":" 12/31/2033","last_update_posted":"2026-03-17"},{"id":"b06c4a15-488d-4c26-b536-d32ff1360c20","acronym":"EINSTEIN-TNBC","url":"https://clinicaltrials.gov/study/NCT07478705","created_at":"2026-03-28T01:41:18.017Z","updated_at":"2026-03-28T01:41:18.017Z","phase":"","brief_title":"Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging","source_id_and_acronym":"NCT07478705 - EINSTEIN-TNBC","lead_sponsor":"Sunnybrook Health Sciences Centre","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2026","start_date":" 05/01/2026","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2026-03-17"},{"id":"503fb49c-7f9c-44d3-9d06-e13901c0cc31","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471815","created_at":"2026-03-28T01:43:58.232Z","updated_at":"2026-03-28T01:43:58.232Z","phase":"Phase 2","brief_title":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","source_id_and_acronym":"NCT07471815","lead_sponsor":"Harbin Medical University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/04/2026","start_date":" 03/04/2026","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2029","study_completion_date":" 03/31/2029","last_update_posted":"2026-03-13"},{"id":"b0107240-c9ff-4b67-b853-211b0d9cdc8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469774","created_at":"2026-03-28T01:44:13.768Z","updated_at":"2026-03-28T01:44:13.768Z","phase":"Phase 1/2","brief_title":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07469774","lead_sponsor":"Biocity Biopharmaceutics Co., Ltd.","biomarkers":" EGFR • BRAF • ALK • MET • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • ALK • MET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/17/2026","start_date":" 03/17/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2026-03-13"},{"id":"f5ce8c06-3250-40ff-b25a-dd3430d92b46","acronym":"","url":"https://clinicaltrials.gov/study/NCT07078604","created_at":"2025-07-26T13:31:46.938Z","updated_at":"2025-07-26T13:31:46.938Z","phase":"Phase 2","brief_title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT07078604","lead_sponsor":"University of Washington","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • daunorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • EP-101 STEMVAC • Leukine (sargramostim)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-07-22"},{"id":"a24dd70d-457e-4bf3-b1b4-2106aa67a692","acronym":"","url":"https://clinicaltrials.gov/study/NCT07064018","created_at":"2025-07-19T14:18:32.626Z","updated_at":"2025-07-19T14:18:32.626Z","phase":"Phase 1/2","brief_title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","source_id_and_acronym":"NCT07064018","lead_sponsor":"University of California, Irvine","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2025-07-14"},{"id":"2451850f-5b0c-4c08-aeda-4faec51709a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07045311","created_at":"2025-07-05T13:59:45.588Z","updated_at":"2025-07-05T13:59:45.588Z","phase":"Phase 2","brief_title":"JS207 Combination Therapy in Triple-negative Breast Cancer","source_id_and_acronym":"NCT07045311","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • bulumtatug fuvedotin (9MW2821)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 03/22/2028","primary_completion_date":" 03/22/2028","study_txt":" Completion: 03/22/2029","study_completion_date":" 03/22/2029","last_update_posted":"2025-07-01"},{"id":"4a3ee118-a60f-43d4-9eb9-1692c44ffa53","acronym":"EXIGENCE","url":"https://clinicaltrials.gov/study/NCT06962163","created_at":"2025-09-07T01:31:13.362Z","updated_at":"2025-09-07T01:31:13.362Z","phase":"","brief_title":"Prospective Study, Assessing Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT06962163 - EXIGENCE","lead_sponsor":"Institut Cancerologie de l'Ouest","biomarkers":" CXCR4","pipe":"","alterations":" ","tags":["CXCR4"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2025-05-20"},{"id":"be1974d5-2bf2-4a09-be82-99d0e9470dde","acronym":"","url":"https://clinicaltrials.gov/study/NCT06965361","created_at":"2025-06-28T16:12:33.153Z","updated_at":"2025-06-28T16:12:33.153Z","phase":"","brief_title":"Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy","source_id_and_acronym":"NCT06965361","lead_sponsor":"Ziauddin University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 01/02/2021","start_date":" 01/02/2021","primary_txt":" Primary completion: 07/31/2022","primary_completion_date":" 07/31/2022","study_txt":" Completion: 07/31/2022","study_completion_date":" 07/31/2022","last_update_posted":"2025-05-16"},{"id":"cab8053f-6a2a-419a-97ce-e6c8bbd0a512","acronym":"NeoCARD","url":"https://clinicaltrials.gov/study/NCT06845319","created_at":"2025-02-27T07:07:22.165Z","updated_at":"2025-02-27T07:07:22.165Z","phase":"Phase 2","brief_title":"Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT06845319 - NeoCARD","lead_sponsor":"Medical University of South Carolina","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-02-25"},{"id":"68ed3b37-b467-4c04-902f-70c0e053d74f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02945579","created_at":"2021-01-18T14:27:45.395Z","updated_at":"2025-02-25T12:26:33.859Z","phase":"","brief_title":"Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy","source_id_and_acronym":"NCT02945579","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/20/2017","start_date":" 01/20/2017","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-24"},{"id":"9ca38f45-d140-4eab-824f-f9c9a32cd7bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01251900","created_at":"2021-01-18T05:02:44.405Z","updated_at":"2025-02-25T12:25:45.095Z","phase":"","brief_title":"BRCA Mutations in Latinas","source_id_and_acronym":"NCT01251900","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Completed","enrollment":" Enrollment 266","initiation":"Initiation: 07/07/2011","start_date":" 07/07/2011","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-24"},{"id":"e5a7e816-2338-4069-ab5a-d3e2d67f258f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04243616","created_at":"2021-01-18T20:37:50.114Z","updated_at":"2025-02-25T12:27:27.130Z","phase":"Phase 2","brief_title":"Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer","source_id_and_acronym":"NCT04243616","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HER-2 • PD-L1 • PGR • PD-L2","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PGR positive","tags":["HER-2 • PD-L1 • PGR • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 07/14/2025","primary_completion_date":" 07/14/2025","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-24"},{"id":"0b405f7d-3f61-4823-b79f-2d25bdb0eeb2","acronym":"SGNPDL1V-001","url":"https://clinicaltrials.gov/study/NCT05208762","created_at":"2023-05-26T17:05:40.425Z","updated_at":"2025-02-25T13:49:21.100Z","phase":"Phase 1","brief_title":"A Study of SGN-PDL1V in Advanced Solid Tumors","source_id_and_acronym":"NCT05208762 - SGNPDL1V-001","lead_sponsor":"Seagen Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PF-08046054"],"overall_status":"Recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 10/25/2022","start_date":" 10/25/2022","primary_txt":" Primary completion: 11/18/2027","primary_completion_date":" 11/18/2027","study_txt":" Completion: 11/17/2028","study_completion_date":" 11/17/2028","last_update_posted":"2025-02-21"},{"id":"1b188a66-2f3c-4c2b-ab05-8f25de4d25c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03808337","created_at":"2021-01-18T18:49:10.340Z","updated_at":"2025-02-25T13:39:43.810Z","phase":"Phase 2","brief_title":"Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease","source_id_and_acronym":"NCT03808337","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR • HER-2 • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • HER-2 • ALK • ROS1"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 01/16/2019","start_date":" 01/16/2019","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-21"},{"id":"1ee7d622-cdd0-4c14-a5ad-ff67b7a251a6","acronym":"NCI-2021-11793","url":"https://clinicaltrials.gov/study/NCT05111561","created_at":"2021-11-08T14:53:11.471Z","updated_at":"2025-02-25T13:40:41.596Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","source_id_and_acronym":"NCT05111561 - NCI-2021-11793","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1","pipe":" | ","alterations":" BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion","tags":["HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • ZEN-3694"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 08/02/2022","start_date":" 08/02/2022","primary_txt":" Primary completion: 03/14/2025","primary_completion_date":" 03/14/2025","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-21"},{"id":"44d24989-a21f-4511-a498-f631f60a4181","acronym":"","url":"https://clinicaltrials.gov/study/NCT03554109","created_at":"2021-01-18T17:29:18.298Z","updated_at":"2025-02-25T13:39:37.796Z","phase":"Phase 2","brief_title":"QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine","source_id_and_acronym":"NCT03554109","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2018","start_date":" 09/01/2018","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 02/09/2022","study_completion_date":" 02/09/2022","last_update_posted":"2025-02-21"},{"id":"688b0cd4-fc6d-4c69-8add-f04838298a5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05491226","created_at":"2022-08-08T12:59:06.885Z","updated_at":"2025-02-25T13:41:10.335Z","phase":"Phase 2","brief_title":"Reinvigorating TNBC Response to Immunotherapy with Combination Myeloid Inhibition and Radiation","source_id_and_acronym":"NCT05491226","lead_sponsor":"Stephen Shiao","biomarkers":" HER-2 • PD-L1","pipe":"","alterations":" ","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Niktimvo (axatilimab-csfr)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 11/17/2023","start_date":" 11/17/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"9563a22f-1431-499b-ba51-cc38d3b74ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04345913","created_at":"2021-01-18T21:01:42.609Z","updated_at":"2025-02-25T13:40:07.851Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT04345913","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PIK3CA • PGR • PTEN","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PIK3CA mutation","tags":["ER • PIK3CA • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-21"},{"id":"c28173c9-ac67-4f97-95aa-85bf990befb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04052555","created_at":"2021-01-18T19:52:14.840Z","updated_at":"2025-02-25T13:39:55.670Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT04052555","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/24/2020","start_date":" 09/24/2020","primary_txt":" Primary completion: 11/20/2025","primary_completion_date":" 11/20/2025","study_txt":" Completion: 11/20/2025","study_completion_date":" 11/20/2025","last_update_posted":"2025-02-21"},{"id":"11ed08db-6adc-4dff-97ee-d51d291166de","acronym":"TRACERX-TNBC","url":"https://clinicaltrials.gov/study/NCT03077776","created_at":"2021-01-18T15:09:42.996Z","updated_at":"2025-02-25T13:52:16.877Z","phase":"","brief_title":"Tracking Triple-negative Breast Cancer Evolution Through Therapy","source_id_and_acronym":"NCT03077776 - TRACERX-TNBC","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 149","initiation":"Initiation: 04/14/2017","start_date":" 04/14/2017","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-20"},{"id":"2a50b5f1-093a-4091-9487-67d57ccd0fe8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04990921","created_at":"2021-08-05T14:53:11.959Z","updated_at":"2025-02-25T13:53:55.184Z","phase":"Phase 2","brief_title":"Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer","source_id_and_acronym":"NCT04990921","lead_sponsor":"University of Louisville","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/02/2021","start_date":" 09/02/2021","primary_txt":" Primary completion: 07/01/2031","primary_completion_date":" 07/01/2031","study_txt":" Completion: 07/01/2031","study_completion_date":" 07/01/2031","last_update_posted":"2025-02-20"},{"id":"5eb63239-f0c2-440d-925c-994f2877adc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00740805","created_at":"2021-01-18T02:47:51.919Z","updated_at":"2025-02-25T13:47:58.987Z","phase":"Phase 1","brief_title":"Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00740805","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • veliparib (ABT-888) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 08/18/2008","start_date":" 08/18/2008","primary_txt":" Primary completion: 09/03/2021","primary_completion_date":" 09/03/2021","study_txt":" Completion: 10/22/2025","study_completion_date":" 10/22/2025","last_update_posted":"2025-02-20"}]